Latest Safety News

Austral Gold has lowered its 2025 production forecast for the Guanaco Mine following a workplace fatality that halted key processing operations. The company has also sold equity holdings to bolster cash flow amid operational disruptions.

OD6 Metals has selected an innovative process flowsheet for its Splinter Rock Rare Earth Project, achieving approximately 75% recovery of key rare earths with superior product purity and optimized costs. This milestone sets the stage for advanced testing and mining studies as the company advances toward production.

Savannah Goldfields is on track to resume gold production at its Georgetown Gold Project by the end of October, with key maintenance and environmental approvals completed.

TerraCom Limited reports a $43.4 million net loss for FY25, reflecting increased impairment charges and operational challenges, while advancing its strategic Moorlands Project in Australia.

Altech Batteries has partnered with AMPower to immediately market and distribute sodium nickel chloride batteries across Europe, Australia, and the USA, fast-tracking revenue ahead of its large-scale CERENERGY project in Germany.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

Lakes Blue Energy has wrapped up drilling at its Wombat-5 well in Victoria’s Gippsland Basin, setting the stage for critical gas flow testing to assess commercial potential.

Starpharma has entered a strategic research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary dendrimer technology, unlocking potential milestone payments of up to AUD $89 million.

MC Mining’s FY2025 results reveal a sharp increase in losses driven by impairments and lower coal sales, while a strategic investment by Kinetic Development Group advances its flagship Makhado Project.

Syntara Limited has reported positive final data from its Phase 2a trial of amsulostat in myelofibrosis, demonstrating significant symptom relief and spleen volume reduction with a favorable safety profile. These results pave the way for advancing clinical development and partnership discussions.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

Newmont Corporation announces the retirement of CEO Tom Palmer at year-end 2025, with President and COO Natascha Viljoen stepping up as the first female CEO in the company’s century-long history.